Skip to content

Randomized Controlled Trial Evaluating the Efficacy of Esketamine in Treating Depression Following Total Laryngectomy: Functional Magnetic Resonance Imaging and Inflammatory Marker Assessment

Randomized Controlled Trial Evaluating the Efficacy of Esketamine in Treating Depression Following Total Laryngectomy: Functional Magnetic Resonance Imaging and Inflammatory Marker Assessment

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109357
Enrollment
Unknown
Registered
2025-09-17
Start date
2025-09-19
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression in patients after total laryngectomy

Interventions

Ketamine Group:Administer 0.5 mg/kg of es ketamine within 30 minutes after anesthesia induction, and provide patient-controlled intravenous analgesia (PCIA) within 48 hours post-surgery. In the PCIA,
Control group:Infuse an equal amount of 0.9% saline within 30 minutes after anesthetic induction, PCIA for 48 hours post-operation, with sufentanil 2ug/kg and 0.25mg of palonosetron hydrochloride dilu

Sponsors

Shandong Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Ages 18-75; 2. American Society of Anesthesiologists (ASA) classification I-III; 3. Patients with laryngeal cancer or hypopharyngeal cancer who are scheduled for total laryngectomy; 4. Good consciousness and unobstructed communication; 5. Voluntarily participating in this study; 6. All signed informed consent forms, received education, and cooperated in data collection.

Exclusion criteria

Exclusion criteria: 1. Cognitive dysfunction; 2. Preoperative mental illness or use of antipsychotic medication; 3. Serious physical diseases such as heart, lung, or brain failure; 4. Drug intolerance; 5. Any other reasons that prevent cooperation with the study.

Design outcomes

Primary

MeasureTime frame
Hospital Anxiety and Depression Scale,(HADS);

Secondary

MeasureTime frame
IL-6?Kyn?Trp?BDNF;Brain Functional Magnetic Resonance Imaging;

Countries

China

Contacts

Public ContactMing Hao

Shandong Second Provincial General Hospital

minghaoslyymz@163.com+86 531 8308 6072

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026